Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

Abstract

Second-line immunosuppressant response was confirmed in 72.2% of irAEs in patients with lung cancer, with lower response rates observed in irAE pneumonitis compared to other irAEs.